New drug ATTO1310 tested for eczema and itch relief
NCT ID NCT06787586
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called ATTO1310 to see if it is safe and how the body processes it. It includes healthy adults, people with atopic dermatitis (eczema), and those with long-term itching. Participants receive either the drug or a placebo and are monitored for side effects and symptom changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
108 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Parts 1 \& 2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 65 years old * Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2 * Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs * Negative pregnancy test for subjects of child-bearing potential * Use of highly effective forms of birth control Part 3 (Subjects with Atopic Dermatitis) Inclusion Criteria: * Any sex or gender who is 18 to 65 years old * Body weight of 50 to 125 kg and BMI between 18.5 and 40 kg/m2 * Clinically confirmed diagnosis of active AD * At least a 1-year history of AD and had no significant flares in AD for at least 4 weeks before Screening * Baseline weekly mean of daily PP-NRS ≥ 7 at Day 1 * EASI score of ≥ 7 at Screening and Day 1 * vIGA-AD score of ≥ 3 at Screening and Day 1 * Use of topical bland emollient (moisturizer) once or twice daily for at least 5 of the 7 days immediately before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study * Negative pregnancy test for subjects of child-bearing potential * Use of highly effective forms of birth control Part 4 (Subjects with Chronic Pruritus) Inclusion Criteria: * Any sex or gender who is 18 to 85 years old * Body weight of 50 to 125 kg, inclusive, and BMI between 18.5 and 40 kg/m2 * Has had chronic pruritus for at least 6 months and is unresponsive to at least a 2-week course of emollient use. * Chronic pruritus that affects at least 2 of the following body areas: legs, arms, or trunk * A single PP-NRS score of ≥ 5 in the 24-hour period prior to the Screening visit * Baseline weekly mean of daily PP-NRS ≥ 7 at Day 1 * Use of a stable dose of topical bland emollient (moisturizer) once or twice daily for at least 2 weeks before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study * Negative pregnancy test for subjects of child-bearing potential * Use of highly effective forms of birth control Parts 1 \& 2 (Healthy Volunteers) Exclusion Criteria: * Any clinically significant underlying illness. * History of malignancy within 5 years of Screening, except adequately treated basal carcinoma or in situ carcinoma of the cervix. * History of major surgery within 8 weeks prior to Day 1 * History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine) * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV * Active or latent tuberculosis infection * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day * History of drug or alcohol abuse * Laboratory values outside of the normal range Exclusion Criteria for Part 3 (Subjects with Atopic Dermatitis): * Any clinically significant underlying illness * History of a clearly defined etiology for pruritus other than AD, including but not limited to urticaria, psoriasis, or other non-atopic dermatologic conditions, hepatic or renal disease, psychogenic pruritus, drug reaction, uncontrolled hyperthyroidism, and infection * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy * History of recurrent eczema herpeticum * History of known primary immunodeficiency, is considered immunocompromised, history of untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months * History of major depression * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine) * Active HBV or HCV or is positive for HIV * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day * ECG with a QTcF \> 450 msec for males or \> 470 msec for females at Screening * History of drug or alcohol abuse * Subject has applied topical corticosteroid in the 14 days preceding Day 1 * Subject has used prohibited medications or therapies during the specified washout period before Day 1 (as defined in the protocol) * Laboratory values outside of the normal range Exclusion Criteria for Part 4 (Subjects with Chronic Pruritus): * Primary dermatologic diagnosis associated with pruritic skin lesions at the time of screening * Regional neuropathic disease associated with pruritus * Severe renal failure requiring dialysis * Untreated cholestatic liver disease * Liver function tests (bilirubin, AST, ALT, alkaline phosphatase) \>2.5 times above the upper limit of normal * History of infectious dermatoses * Suspected diagnosis of somatoform pruritus * Suspected diagnosis of drug-induced pruritus * History of malignancy within 5 years of Screening * History of unexplained fevers, night sweats, or unintentional weight loss * Major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy * History of known primary immunodeficiency, is considered immunocompromised, untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months * History of attempted suicide * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine) * Active HBV or HCV or is positive for HIV. * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day * ECG with a QTcF \> 450 msec for males or \> 470 msec for females at Screening * History of drug or alcohol abuse * Use of prohibited medications as defined in the Protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences
Montreal, Quebec, H3P 3P1, Canada
-
Attovia Clinical Site 102
Plainfield, Indiana, 46168, United States
-
Attovia Clinical Site 103
Encinitas, California, 92024, United States
-
Attovia Clinical Site 104
Saint Joseph, Missouri, 64506, United States
-
Attovia Clinical Site 105
Montreal, Quebec, H2X2V1, Canada
-
Attovia Clinical Site 106
Reno, Nevada, 89509, United States
-
Attovia Clinical Site 107
Sacramento, California, 95815, United States
-
Attovia Clinical Site 108
San Antonio, Texas, 78213, United States
-
Attovia Clinical Site 109
Coral Gables, Florida, 33134, United States
-
Attovia Clinical Site 110
Fredericton, New Brunswick, E3B1G9, Canada
-
Attovia Clinical Site 111
Newmarket, Ontario, L3Y 5G8, Canada
-
Attovia Clinical Site 112
Peterborough, Ontario, K9J 5K2, Canada
-
Attovia Clinical Site 113
Toronto, Ontario, M4W 2N4, Canada
-
Attovia Clinical Site 114
New York, New York, 10029, United States
-
Attovia Clinical Site 116
Rocklin, California, 95765, United States
-
Attovia Clinical Site 118
Margate, Florida, 33063, United States
-
Attovia Clinical Site 119
New York, New York, 10128, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.